vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and BRAND HOUSE COLLECTIVE, INC. (TBHC). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $103.5M, roughly 1.8× BRAND HOUSE COLLECTIVE, INC.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -9.6%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -21.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Soho House is an international private members’ club with a focus on the media, arts and fashion industries.
AXSM vs TBHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $103.5M |
| Net Profit | — | $-3.7M |
| Gross Margin | — | 20.4% |
| Operating Margin | -33.1% | -1.9% |
| Net Margin | — | -3.6% |
| Revenue YoY | 57.4% | -9.6% |
| Net Profit YoY | — | 51.8% |
| EPS (diluted) | — | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $103.5M | ||
| Q3 25 | $171.0M | $75.8M | ||
| Q2 25 | $150.0M | $81.5M | ||
| Q1 25 | $121.5M | $148.9M | ||
| Q4 24 | $118.8M | $114.4M | ||
| Q3 24 | $104.8M | $86.3M | ||
| Q2 24 | $87.2M | $91.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-3.7M | ||
| Q3 25 | $-47.2M | $-20.2M | ||
| Q2 25 | $-48.0M | $-11.8M | ||
| Q1 25 | $-59.4M | $7.9M | ||
| Q4 24 | $-74.9M | $-7.7M | ||
| Q3 24 | $-64.6M | $-14.5M | ||
| Q2 24 | $-79.3M | $-8.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 20.4% | ||
| Q3 25 | — | 16.3% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | 30.3% | ||
| Q4 24 | — | 28.1% | ||
| Q3 24 | — | 20.5% | ||
| Q2 24 | — | 29.5% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -1.9% | ||
| Q3 25 | -27.0% | -24.7% | ||
| Q2 25 | -24.5% | -12.9% | ||
| Q1 25 | -46.9% | 6.2% | ||
| Q4 24 | -61.1% | -2.1% | ||
| Q3 24 | -59.8% | -15.4% | ||
| Q2 24 | -89.5% | -8.2% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -3.6% | ||
| Q3 25 | -27.6% | -26.6% | ||
| Q2 25 | -32.0% | -14.5% | ||
| Q1 25 | -48.9% | 5.3% | ||
| Q4 24 | -63.1% | -6.7% | ||
| Q3 24 | -61.7% | -16.8% | ||
| Q2 24 | -91.0% | -9.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.16 | ||
| Q3 25 | $-0.94 | $-0.90 | ||
| Q2 25 | $-0.97 | $-0.54 | ||
| Q1 25 | $-1.22 | $0.61 | ||
| Q4 24 | $-1.54 | $-0.59 | ||
| Q3 24 | $-1.34 | $-1.11 | ||
| Q2 24 | $-1.67 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $6.5M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $-44.0M |
| Total Assets | $713.6M | $229.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $6.5M | ||
| Q3 25 | $325.3M | $3.6M | ||
| Q2 25 | $303.0M | $3.5M | ||
| Q1 25 | $300.9M | $3.8M | ||
| Q4 24 | $315.4M | $6.8M | ||
| Q3 24 | $327.3M | $4.5M | ||
| Q2 24 | $315.7M | $3.8M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.0M | ||
| Q4 24 | — | $85.8M | ||
| Q3 24 | — | $61.4M | ||
| Q2 24 | — | $47.5M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $-44.0M | ||
| Q3 25 | $73.7M | $-35.2M | ||
| Q2 25 | $73.1M | $-16.2M | ||
| Q1 25 | $53.2M | $-19.0M | ||
| Q4 24 | $57.0M | $-27.1M | ||
| Q3 24 | $92.9M | $-19.7M | ||
| Q2 24 | $102.9M | $-5.5M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $229.2M | ||
| Q3 25 | $669.3M | $221.9M | ||
| Q2 25 | $639.8M | $225.4M | ||
| Q1 25 | $596.7M | $242.2M | ||
| Q4 24 | $568.5M | $279.8M | ||
| Q3 24 | $561.5M | $266.2M | ||
| Q2 24 | $548.2M | $242.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.9M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -25.9% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-25.9M | ||
| Q3 25 | $1.0M | $-7.0M | ||
| Q2 25 | $-32.4M | $-3.1M | ||
| Q1 25 | $-43.4M | $19.8M | ||
| Q4 24 | $-26.2M | $-12.6M | ||
| Q3 24 | $-18.6M | $-12.7M | ||
| Q2 24 | $-30.1M | $-13.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-26.8M | ||
| Q3 25 | $988.0K | $-7.4M | ||
| Q2 25 | $-32.4M | $-3.6M | ||
| Q1 25 | $-43.7M | $19.0M | ||
| Q4 24 | $-26.2M | $-13.1M | ||
| Q3 24 | $-18.7M | $-13.2M | ||
| Q2 24 | $-30.2M | $-14.4M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -25.9% | ||
| Q3 25 | 0.6% | -9.8% | ||
| Q2 25 | -21.6% | -4.5% | ||
| Q1 25 | -36.0% | 12.8% | ||
| Q4 24 | -22.1% | -11.5% | ||
| Q3 24 | -17.9% | -15.2% | ||
| Q2 24 | -34.6% | -15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.3% | 0.5% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.1% | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TBHC
Segment breakdown not available.
